The Masterclass held in Florence in November represented a precious moment of dissemination, updating and discussion of the state of the art on hypertrophic obstructive cardiomyopathy with an eye to future prospects. The numerous experts present provided a global and in-depth vision of the various topics concerning the disease: modern technologies, genetic testing, therapies.
We invite you to the webinar on December 17 at 18 pm where we will discuss the following topics: Hypertrophic obstructive cardiomyopathy: updates on the AIFA resolution regarding the reimbursement of mavacamtem and The importance of CPR training: when every minute can save a life
AICARM inaugurated a new format of information and training in Florence. The Cardiomyopathy Day involved doctors, patients and family members in two distinct sections: the in-depth and updating interventions of the experts and the testimonies and exchange of ideas and experiences of the patients. While the CPR courses continued at the headquarters
AICARM announces its patronage of the Masterclass on Hypertrophic Obstructive Cardiomyopathy to be held in Florence on 26-27 November 2024. The course offers an update on the pathophysiology, diagnosis and treatment of hypertrophic cardiomyopathy, based on over 40 years of clinical experience at Careggi Hospital in Florence, with experts from other Italian institutions. Lectures and practical workshops on genetic diagnosis, new therapies and discrepancies between guidelines and clinical practice are planned. The aim is to promote the formation of expert teams on the national territory.
AICARM announces its patronage of the "Roma Cardiomyopathies" congress on 18-19 October 2024 in Rome, aimed at strengthening collaboration between cardiologies in the management of heart muscle diseases and rare diseases. The event promotes the exchange of experiences between Italian cardiology schools, supporting professional growth and the creation of a network. AICARM invites cardiologists and specialists to participate.
The Hypertrophic Obstructive Cardiomyopathy Treatment course is designed to present the impact of obstruction on the quality of life and prognosis of patients with hypertrophic obstructive cardiomyopathy. The experiences gained so far with "classic" drugs, such as beta-blockers capable of effectively and safely reducing outflow obstruction and, in some cases, postponing or avoiding surgery, will be discussed. Over the last 2 decades, cardiac surgical experience with myectomy and mitral plasty have significantly improved patients' symptoms and their prognosis. With the introduction of Mavacamten, already available for "compassionate use" for patients over 18 years of age, and perhaps Aficamten in the future, there are prospects for long-term treatment, which currently makes it more suitable for elderly patients and in the future, perhaps, also in young patients, in whom cardiac surgery currently remains a fundamental solution.
The course aims to provide a comprehensive and updated overview of the pathophysiology, diagnostics and treatment of patients with cardiomyopathies, with the precious contribution of experts operating in prestigious national institutions. The topics covered are extremely broad and new, from genetic diagnosis to new pharmacological and gene therapy perspectives. Clinical cases will be presented, with discussion of the different possible options in the decision making process, with the evaluation of the ECG, echocardiogram, cardiac MRI, and more complex invasive tests. up to the interpretation of the genetic analysis. All teaching staff have specific experience in the sector.
More than 150 participants including members, sponsors and speakers, mainly from Tuscany and with teachers from all over Italy. These are the numbers of the Masterclass Hypertrophic Cardiomyopathy and Cardiac Amyloidosis which took place on 8 and 9 June 2023 in the Auditorium of the Florence Cathedral.
The II MASTERCLASS - HYPERTROPHIC CARDIOMYOPATHY AND CARDIAC AMYLOIDOSIS will be held in Florence on 8 and 9 June, under the patronage of AICARM Onlus. The course aims to provide participants with an exhaustive and updated framework on the pathophysiology, diagnosis and treatment of patients with hypertrophic phenotype cardiomyopathies and amyloidosis, transmitting the clinical and research experience gained in over 40 years in the Florence Center at Careggi and at the Meyer, with the valuable contribution of experts from prestigious national institutions.
On 13 April 2023 AICARM, at the request of the organizers of the congress "Advances in pediatric heart failure: congenital heart disease and cardiomyopathies", underway in Florence, hosted a meeting dedicated to the new perspectives for the use of "gene therapy for the treatment of cardiomyopathies.